Perspective Therapeutics’ (CATX) Outperform Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a report published on Monday morning,Benzinga reports. Wedbush currently has a $11.00 target price on the stock.

A number of other research analysts have also recently commented on CATX. B. Riley Financial raised their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Royal Bank Of Canada cut their price target on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, March 17th. Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. Piper Sandler began coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target for the company. Finally, UBS Group raised their price target on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.63.

Perspective Therapeutics Trading Up 1.5%

Shares of CATX opened at $4.71 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16. The company has a 50-day moving average price of $4.77 and a two-hundred day moving average price of $3.60.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The business had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. On average, research analysts predict that Perspective Therapeutics will post -1.17 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares during the last quarter. Avidity Partners Management LP raised its stake in shares of Perspective Therapeutics by 7.2% in the fourth quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after acquiring an additional 216,700 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares during the last quarter. Opaleye Management Inc. bought a new position in shares of Perspective Therapeutics in the fourth quarter valued at approximately $3,257,000. Finally, State Street Corp raised its stake in shares of Perspective Therapeutics by 3.3% in the fourth quarter. State Street Corp now owns 1,141,247 shares of the company’s stock valued at $3,138,000 after acquiring an additional 36,543 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.